/

Sociétés

AI

Non vérifié

AIM ImmunoTech Inc.

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueOncologieSantéVIH, SIDA et maladies auto-immunes

14 communiqués de presse

Voir tous les communiqués de presse

03/11/2025

Biotechnologie

Loi/Droit/Fiscalité

Médecine Santé Bien-être

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

04/09/2025

Biotechnologie

Médecine Santé Bien-être

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

28/02/2025

Biotechnologie

Annonces Économiques

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

17/12/2024

Oncologie

Santé

VIH, SIDA et maladies auto-immunes

Biotechnologie

Médecine - Divers

Industrie pharmaceutique

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

16/12/2024

Science

Finance

Médecine - Divers

Associations/Professionnels

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

12/12/2024

Science

Finance

Biotechnologie

Médecine - Divers

Associations/Professionnels

Industrie pharmaceutique

Santé

Oncologie

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

12/12/2024

Biotechnologie

Annonces Économiques

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

10/12/2024

Oncologie

Santé

VIH, SIDA et maladies auto-immunes

Santé Publique

Industrie pharmaceutique

Biotechnologie

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

05/12/2024

Science

Finance

Médecine - Divers

Associations/Professionnels

Biotechnologie

Industrie pharmaceutique

Santé

Oncologie

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

02/12/2024

Biotechnologie

VIH, SIDA et maladies auto-immunes

Santé

Industrie pharmaceutique

Oncologie

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group’s Nominees to the Board

Source

AIM ImmunoTech Inc.

Émetteur

1.00

0

Followers

0

Compatibilité

0